Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Buys Dx Rights to Genizon Research Programs, Takes Equity Stake in Firm

NEW YORK (GenomeWeb News) - Genizon Biosciences and pharmaceutical giant Pfizer have reached a licensing and collaboration agreement that gives Pfizer diagnostic rights to Genizon's research programs in Alzheimer's, attention deficit hyperactivity disorder, and endometriosis.
 
Pfizer has agreed to pay Genizon upfront license fees and will also fund the company’s research on genetic variations associated with those diseases. Pfizer will also buy an equity stake in the company, subject to certain closing conditions.
 
Genizon retains therapeutic rights to the research programs.
 
The companies will collaborate on the discovery of diagnostic markers based on Genizon’s ongoing genome-wide association studies of the Quebec Founder Population. Genizon said that the "unique genetic heritage" of the Quebec Founder Population offers opportunities to find genetic markers to predict disease susceptibility.
 
The companies plan to compare the data derived from these studies against data from other genome-wide association studies from conducted in "general populations."

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.